These findings may have direct implications for GFI1 as a therapeutic target in malignancies where GFI1 is involved such as T-cell leukemia, neuroendocrine lung carcinomas28, and in medulloblastoma, where it is believed to be a driving oncogene in certain aggressive subgroups29. The gene discussed is GFI1; the disease is T-cell leukemia.